Clinical trial
Phase III Randomized Clinical Trial to Evaluate the Efficacy and Safety of Twice-Daily Hyperfractionated Dose-Escalated Thoracic Radiotherapy in Patients With Limited-Stage Small Cell Lung Cancer (ESCALADOR Study)
NCT07015892 is registered in ClinicalTrials.gov with Instituto de Investigación Biomédica de Salamanca as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Phase III Randomized Clinical Trial to Evaluate the Efficacy and Safety of Twice-Daily Hyperfractionated Dose-Escalated Thoracic Radiotherapy in Patients With Limited-Stage Small Cell Lung Cancer (ESCALADOR Study)
- Lead sponsor
- Instituto de Investigación Biomédica de Salamanca
- Phase
- Phase 3
- Overall status
- Recruiting
- Start date
- March 1, 2026
- Completion date
- December 31, 2028
- Enrollment
- 300 (estimated)
- Sites
- 13
Conditions
As the registry lists them; a condition with its own page is linked.